“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Tuesday, August 26, 2025

Acadia Pharmaceuticals


Acadia Pharmaceuticals – Product Catalog (A–Z)

Approved Medicines

  • DAYBUE® → Generic: trofinetide → Indication: Rett syndrome (first FDA-approved therapy) → Dose: Oral solution; weight-based dosing

  • NUPLAZID® → Generic: pimavanserin → Indication: Hallucinations and delusions associated with Parkinson’s disease psychosis → Dose: Tablets (34 mg capsule; also 10 mg for certain cases)

Investigational Pipeline

  • ACP-204 (Remlifanserin) → Next-generation 5-HT2A inverse agonist → Indication: Alzheimer’s disease psychosis, Lewy body dementia → Phase III development

  • ACP-101 → Investigational therapy for Prader-Willi syndrome → Late-stage clinical development



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)